Publications
Publications
Show Results For
- All HBS Web
(135)
- Faculty Publications (26)
Genes
→
Page 1 of 26
Results →
- January 2024 (Revised April 2024)
- Case
Target Malaria: Editing Mosquitoes through Gene Drives
By: Shikhar Ghosh and Shweta Bagai
Target Malaria, a non-profit research consortium, is exploring the application of CRISPR-Cas9 gene editing technology to combat malaria in Sub-Saharan Africa. Its approach uses gene drives, a revolutionary tool, to suppress the population of malaria-carrying... View Details
- July 2023
- Teaching Note
Saham Group: It's In the Genes
By: Christina R. Wing and Esel Çekin
Teaching Note for HBS Case No. 621-069. View Details
- June 2023
- Case
Verve Therapeutics: Taking DNA Editing to Heart
By: Shikhar Ghosh and Shweta Bagai
Verve Therapeutics, a public biotech company based in Boston, created a novel approach to addressing cardiovascular disease (CVD) - a leading cause of deaths globally. The company's approach was a single shot treatment to permanently lower cholesterol, thus reducing... View Details
- April 2023
- Case
Drive Capital: A New Road for Venture
By: Paul A. Gompers and Alicia Dadlani
Founded by two former Sequoia Capital partners, Columbus-Ohio-based Drive Capital’s mission was to build a world-class venture capital firm in the middle of the U.S., an area historically overlooked by VCs. Drive faced early challenges of attracting investors, sourcing... View Details
- March 2023
- Case
Moderna
By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen and Dave Habeeb
This multimedia case follows the story of Moderna and its entry into vaccine development in the wake of the COVID-19 pandemic. In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19.... View Details
- December 2021 (Revised June 2022)
- Case
Darden Restaurants: The Nine Square Feet
By: Joshua D. Margolis and James Barnett
In June 2021, Darden Restaurants CEO Gene Lee contemplates how to position the world’s biggest full-service restaurant more than one year into the COVID-19 pandemic. View Details
- September 15, 2021
- Article
Improving Deconvolution Methods in Biology Through Open Innovation Competitions: An Application to the Connectivity Map
By: Andrea Blasco, Ted Natoli, Michael G. Endres, Rinat A. Sergeev, Steven Randazzo, Jin Hyun Paik, N.J. Maximilian Macaluso, Rajiv Narayan, Xiaodong Lu, David Peck, Karim R. Lakhani and Aravind Subramanian
A recurring problem in biomedical research is how to isolate signals of distinct populations (cell types, tissues, and genes) from composite measures obtained by a single analyte or sensor. Existing computational deconvolution approaches work well in many specific... View Details
- January 2021
- Case
Saham Group: It's In the Genes
By: Christina R. Wing and Gamze Yucaoglu
The case opens in August 2020 as Moulay Mhamed Elalamy (Mhamed), CEO of the Saham Group (the Group), a pan-African investment company that operates a variety of businesses out of Morocco, contemplates the Group’s identity, its investment strategy, and how to navigate... View Details
- September 2020 (Revised July 2021)
- Case
Moderna (A)
By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer and Kerry Herman
In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19. The case explores how a company builds a digital organization, and leverages artificial intelligence and other digital... View Details
- September–October 2020
- Article
The Past, Present, and (Near) Future of Gene Therapy and Gene Editing
By: Julia Pian, Amitabh Chandra and Ariel Dora Stern
Emerging gene therapy and gene-editing technologies will have a growing impact on patient lives and health-care delivery. We analyzed a decade of data on clinical trials and venture capital investments to understand the likely trajectory of genetically focused... View Details
- Article
Common Variants of the Oxytocin Receptor Gene Do Not Predict the Positive Mood Benefits of Prosocial Spending
By: Ashley V. Whillans, Lara B. Aknin, Colin Ross, Lihan Chen and Frances S. Chen
Who benefits most from helping others? Previous research suggests that common polymorphisms of the oxytocin receptor gene (OXTR) predict whether people behave generously and experience increases in positive mood in response to socially-focused experiences in daily... View Details
- Article
Advancing Computational Biology and Bioinformatics Research Through Open Innovation Competitions
By: Andrea Blasco, Michael G. Endres, Rinat A. Sergeev, Anup Jonchhe, Max Macaluso, Rajiv Narayan, Ted Natoli, Jin H. Paik, Bryan Briney, Chunlei Wu, Andrew I. Su, Aravind Subramanian and Karim R. Lakhani
Open data science and algorithm development competitions offer a unique avenue for rapid discovery of better computational strategies. We highlight three examples in computational biology and bioinformatics research where the use of competitions has yielded significant... View Details
- March 2018 (Revised September 2018)
- Case
Gene Lee Navigates the Darden Takeover
By: Joshua D. Margolis, H. Lawrence Culp, James Barnett and Aldo Sesia
Following a full takeover of Darden Restaurant’s Board of Directors, Darden COO Gene Lee is weighing an offer to become interim CEO. View Details
- October 2016 (Revised September 2017)
- Case
The CRISPR-Cas9 Quarrel
By: Richard G. Hamermesh and Matthew G. Preble
In mid-2016, the Broad Institute and the University of California, Berkeley were in the middle of a contentious patent dispute over which entity controlled a breakthrough gene editing technology called CRISPR-Cas9. With CRISPR-Cas9, scientists might soon be able to... View Details
- February 2014
- Case
BGI: Data-driven Research
By: Willy Shih and Sen Chai
BGI has the largest installed gene-sequencing capacity in the world, and to Zhang Gengyun, general manager of the Life Sciences Division, this represented an opportunity to apply his training as a plant breeder and his early career work as a biochemist to improving... View Details
Keywords: Genomics; Gene Sequencing; Life Sciences; Plant Breeding; Human Genome Program; Beijing Genomics Institute; BGI; Rice Genome; Technological Innovation; Innovation Strategy; Research; Research and Development; Science; Genetics; Science-Based Business; Strategy; Commercialization; Corporate Strategy; Information Technology; Applications and Software; Agriculture and Agribusiness Industry; Biotechnology Industry; Food and Beverage Industry; China; United States
- December 2012
- Teaching Note
Gene Patents (A) (TN)
By: Richard G. Hamermesh and Matthew Preble
This is the teaching note for case Gene Patents (A). In March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our... View Details
- March 2012 (Revised October 2013)
- Supplement
Gene Patents (B)
By: Richard Hamermesh and Phillip Andrews
The case updates events since the Court's ruling against Myriad Genetics on March 29, 2010 and should be used in conjunction with Gene Patents (A). On July 29, 2011, a US Appeals Court reversed the prior ruling against Myriad. On September 16, 2011, the first major... View Details
Keywords: Courts and Trials; Patents; Genetics; Judgments; Investment; Biotechnology Industry; United States
- October 2011
- Case
Gene Sequencing: Staking a Position in an Expanding Industry
By: Richard G. Hamermesh, Mara Aspinall and Phillip Andrews
Towards the end of 2010, companies in the gene sequencing industry were pushing aggressive R&D programs to develop technologies and products in the race to sequence the entire human genome at a cost of $1,000. It remained to be seen when the "$1,000 genome" would... View Details
- June 2011 (Revised October 2013)
- Case
Gene Patents (A)
By: Richard Hamermesh, David Kiron and Phillip Andrews
In March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our increasing knowledge of the Human Genome. The case issues... View Details
- November 2009 (Revised March 2010)
- Case
Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story
By: Richard G. Hamermesh, Raju Kucherlapati and Rachel Gordon
In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had... View Details